Crescendo Biologics Company
Crescendo Biologics is engaged in the development of a proprietary drug portfolio based on their VH antibody fragment platform.
Technology:
Atrificial Vectors and Immune Cells
Industry:
Healthcare
Headquarters:
Cambridge, Cambridgeshire, United Kingdom
Founded Date:
2007-01-01
Employees Number:
51-100
Funding Status:
Series B
Investors Number:
14
Total Funding:
79000000
Estimated Revenue:
$1M to $10M
Last Funding Date:
2018-04-30
Last Funding Type:
Series B
Register and Claim Ownership